2023 annual financial data
China SXT Pharmaceuticals 2023 Financial results
Direct answer
Revenue was 1,971,679 USD.
Operating income was -5,607,509 USD and net income was -5,934,772 USD.
Operating cash flow was -80,757 USD.
Get free China SXT Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,971,679 USD
- Operating income
- -5,607,509 USD
- Net income
- -5,934,772 USD
- Operating cash flow
- -80,757 USD
Explore related company data
View all 2023 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Net marginView Operating cash flow marginView all China SXT Pharmaceuticals financial years